Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Alcoa ( AA) downgraded at Citigroup from Buy to Hold, Citigroup said. $17 price target. Estimates also cut ahead of earnings, because of a weaker dollar and higher input costs.

Apple ( AAPL) rated new Outperform at Wedbush. $405 price target. Company should be able to keep gaining market share.

Acorda Therapeutics ( ACOR)upgraded at Leerink to Outperform. Ampyra prescriptions should begin to ramp up soon.

Autodesk ( ADSK) upgraded at Goldman from Neutral to Buy. Company is leveraged to late-cycle growth and could see margin expansion. $50 price target.

Abercrombie & Fitch ( ANF) rated new Neutral at Wedbush. $60 price target. Stock is already pricing in a rebound in sales and comps.

Atheros ( ATHR) downgraded at Piper to Neutral. QCOM purchase makes sense for both parties. $45 price target.

Avon ( AVP) downgraded at UBS from Buy to Neutral. $32 price target. Company is seeing lower returns, despite deep cost-cutting.

Boeing ( BA) downgraded at Argus from Buy to Hold. 787 delays and defense spending cuts are not yet priced into the stock.

Franklin Resources ( BEN) downgraded at FBR from Market Perform to Underperform. $125 price target. Investors are moving away from fixed-income funds.

Barnes & Noble ( BKS) upgraded at Credit Suisse to Neutral from Underperform as competitor struggles may limit downside near term, Credit Suisse said. Price target boosted to $16 from $10.

Brookfield Properties ( BPO) initiated at Barclays with an Equal Weight rating and $18 price target. The global pure-play office company will continue its strong external growth potential, Barclays said.

Boyd Gaming ( BYD) upgraded at Barclays to Overweight from Equal Weight as Las Vegas market is poised for recovery in 2011 and Borgata is performing better than expected, Barclays said. Price target raised to $13 from $7.

Colgate-Palmolive ( CL) downgraded at UBS from Buy to Neutral, UBS said. Valuation call, based on an $84 price target.

Clorox ( CLX) estimates, target lowered at UBS. CLX estimates were cut through 2012, UBS said. Company cut its guidance, but should buy back more stock in the new year. Buy rating and new $72 price target.

If you liked this article you might like

Is an Avon Bottom Calling?

Avon Still Has Value But Isn't Investable, Barclays Says

Closing Bell: Another Record for Dow Stretches Streak Into Day Seven; Avon Tumbles